An Update on Developments in Female Hormonal Contraception

Total Page:16

File Type:pdf, Size:1020Kb

An Update on Developments in Female Hormonal Contraception Send Orders of Reprints at [email protected] 276 Current Women’s Health Reviews, 2012, 8, 276-288 An Update on Developments in Female Hormonal Contraception Deborah A. Garside1, Ayman Gebril2, Natalie Nimmo2, Manal Alsaadi2, Alexander B. Mullen2 and Valerie A. Ferro2,* 1Imperial College London, Faculty of Medicine, London, SW7 2AZ, UK; 2University of Strathclyde, Strathclyde Insititute of Pharmacy and Biomedical Sciences, 161 Cathedral Street, Glasgow, G4 0RE, UK Abstract: The human population continues to grow in some parts of the world, which has severe impact on resources, health and the environment. Individually, contraception enables women to choose their optimal family size and birth spacing, while in resource-poor countries it can help lift families out of poverty. While the oral contraceptive pill revolutionised female contraceptive options, there was a price to pay in terms of increased health risks. Today, improved formulations have been developed, together with non-oral hormonal technologies. This review will examine the history of female contraceptive research and provide an update on the status and future direction of new products. Keywords: Combined formulations, contraception, devices, hormones, implants, oestrogen, oral, progestogen. HUMAN POPULATION GROWTH various types of contraception is available to most women in the developed world, this is not generally the case for those The statistics on human population growth present a in developing countries. There is therefore a significant confusing picture, making it necessary to ask whether there unmet need for contraception that meets the particular health is a continuing need for contraceptive research. The and cultural needs of women in these countries. For population growth rate over 5 years (2005-2010) is shown in example, Fig. (2a and 2b) show the percentage number of Fig. (1). In 2011, the global population reached 7 billion women using some method of contraception and areas of the people and is expected to expand to 10.1 billion by the end world where there is still an unmet need for family planning, of this century [1]. However, individual regions show vast respectively. Clearly safe, and effective population control is differences in terms of birth, death and population growth rates. The latter can be divided into four categories - less still needed to address regio-specific patterns, but it is critical than 0% (in decline), less than 1% (low), 1-2% (moderate) that whatever methods are available, that they are readily and greater or equal to 2% (rapid) growth per anuum. These accessible and not subject to economic constraints. Methods have significant impacts which are summarised in Table 1, being developed should also take into account efficacy, side- and it is clear that there are many challenges, albeit different effects, ease of use, including the need for the user to ones, still being faced at both ends of the growth spectrum. remember repeat administrations, cultural factors and Furthermore, overall, the world’s total fertility rate has fallen convenience of application [4]. These therefore provide significantly from the 1950s to the present day, from 5 to 2.6 drivers for innovations in the modern contraceptive field. children per woman – this is attributed to widespread use of contraceptives [2]. However, in the poorest countries CONTRACEPTION THROUGH THE AGES maternal mortality continues to be high. The numbers of Limiting the number of pregnancies is not a modern deaths were 2.91 million in 1990-1995, and only fell to 2.76 phenomenon. Behavioural methods (abstinence, coitus million in the following 5 years. inerruptus, avoidance during certain times of a cycle, breast- Stover and Ross [3] have described in detail how feeding) have played a major role, along with barrier effective family planning can reduce the number of these methods, chemical intervention (including use of natural deaths by: reducing the number of births; averting high-risk products since ancient times and contemporary spermicidal births and preventing the number of abortions, with methods), intrauterine devices (IUD) and sterilisation [5-8]. associated health risks. Importantly, therefore, access to However, by far the most influential contraception method in suitable, effective and affordable contraception is a key issue modern times has been hormonal control, brought about by for global women’s health. The ability for women not to be the advent of the oral contraceptive pill. able to choose when they are pregnant and how many children they have, can have a profound effect on their HISTORY OF THE ORAL CONTRACEPTIVE PILL health, education and socio-economic status. While access to Since its inception, the oral contraceptive (OC) pill has, and continues to evoke controversy on various levels (cultural, economic, ethical, medical, moral, political, *Address correspondence to this author at the University of Strathclyde, religious and social). The historic context leading to the Strathclyde Insititute of Pharmacy and Biomedical Sciences, 161 Cathedral Street, Glasgow, G4 0RE, UK; Tel: +44 141 548 3724; Fax: +44 141 552 2562; launch of the “Pill” in terms of scientific and personal trials E-mail: [email protected] faced by individuals and the approaches taken by the 1875-6581 $58.00+.00 © 2012 Bentham Science Publishers Female Hormonal Contraception Current Women’s Health Reviews, 2012, Vol. 8, No. 4 277 Fig. (1). Population growth rate by country (Data from [1]). Table 1. Population Growth Category and Impacts (Summarised from [105]) % Population Growth Regions Impacts Rate Per Annum Less than 0 Japan, Germany, Russia, eastern Europe • Widespread use of contraception (sub-replacement • Greatest ageing population impact fertility, low mortality) • Encourages economic migration 0-1 USA, Canada, much of Europe, • Widespread use of contraception (low fertility, low China, Brazil • Ageing population dependent on public resources for support mortality) • Major effect on global environment stresses 1-2 India, Indonesia, north Africa, • Widespread use of contraception (declining fertility, low western Latin America • Less time spent in childrearing, so more women in employment mortality) • High labour force, fewer young or old dependents – economic benefits • Reduced stress on public services and infrastructure Greater or equal to 2 Sub-Saharan Africa, • Poor use of contraception (relatively high fertility Pakistan, Afghanistan, • Childbearing at very young and advanced ages, with short birth intervals and moderate to low Arabian peninsula • Pressure on public services and infrastructure mortality) • Stress on environment • Reduced economic growth and inadequate healthcare systems • Increased maternal and child mortality pharmaceutical companies, is far more interesting than the menstrual disorders, however, it was only in 1961 that subsequent lack of innovation in the field [reviewed by [9- approval was given for a contraceptive (75µg mestranol/5mg 12]. Nevertheless, the Pill has survived for over half a norethynodrel) to be used by married women in the US. The century and is likely to be hailed as one of the twentieth “Pill” revolutionised society, although it took another decade century’s greatest “life-changing” scientific drugs. Since the before unmarried women were allowed access to OCs [10]. 1920s, there were a number of key players and milestones 1 While the early OCs were based on oestrogens or (summarised in Textbox 1) that influenced the launch of progestogens, for safety reasons and improved cycle control, Searle’s Enovid™ (which contained the actives 150µg mestranol/9.85mg norethynodrel). It was approved by the Food and Drug Administration (FDA) in 1957 to treat 1oestrogen and estrogen are used interchangeably 278 Current Women’s Health Reviews, 2012, Vol. 8, No. 4 Garside et al. Fig. (2). (a). Percentage of women using some method of contraception among those aged 15-49 who are married or in a union (Data from [1]). (b). Percentage of women with an unmet need for family planning among those aged 15-49 who are married or in a union (Data from [1]). Text Box 1. Timeline of Discoveries Leading to the First Contraceptive Pill 1921: Ludwig Haberlandt coined the term hormonal sterilisation and demonstrated in rabbits and guinea pigs that ovulation could be temporarily suppressed by transplanting ovaries from pregnant animals into recipients [125]. For human studies, since surgery was not an option, the company Gideon Richter produced the preparation Infecundin that enabled Haberlandt to investigate the use of parenterally or orally administered ovary extracts, to induce sterility [9, 126]. 1929: Adolf Butenandt isolated estrone, a female sex hormone, and in the early 1930s he and other researchers isolated progesterone from pig ovaries [127]. 1936: AW Makepeace demonstrated the anti-ovulatory effect of progesterone [128], however, extraction from animal ovaries made it expensive for a commercial product. 1941: Russell Marker developed a more cost effective chemical synthesis method by extracting diosgenin from Mexican wild yam (Dioscorea) roots [129] and founded the company Syntex. 1951: Carl Djerassi working at Syntex produced the first progestin (or progestogen) in the form of the steroid norethistrone, which was orally active and an advancement of any other progestational hormone [130]. A year later, Frank Colton at Searle Company developed a close isomer of norethistrone, norethynodrel [10]. 1951: Margaret Sanger (founder of the Planned Parenthood Federation
Recommended publications
  • University of Groningen the Pill and Thrombosis Van Vlijmen, Elizabeth
    University of Groningen The pill and thrombosis van Vlijmen, Elizabeth Femma Willemien IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2016 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): van Vlijmen, E. F. W. (2016). The pill and thrombosis. Rijksuniversiteit Groningen. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne- amendment. Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 08-10-2021 Financial support for the printing of this thesis was kindly provided by the Dutch Medicines Evaluation Board and UMCG/GUIDE.
    [Show full text]
  • Abnormal Uterine Bleeding: Strategies for Management”
    PRE-CONGRESS COURSE 4 SIG Endometriosis & Endometrium “Abnormal uterine bleeding: strategies for management” CONTENTS Program overview p. 1 Speakers’ contributions • Abnormalities of menstrual bleeding: getting our terminologies right - I. Fraser (AUS) p. 3 • Abnormal uterine bleeding: the patient perspective - P. Warner (UK) p. 13 • Optimising strategies for evaluation and management of abnormal uterine bleeding - A. Prentice (UK) p. 32 • Unscheduled bleeding with exogenous hormone administration – P. Rogers (AUS) p. 33 • Strategies to control; endometrial bleeding - D. Archer (USA) p. 46 • Local mechanisms responsible for endometrial bleeding - H. Critchley (UK) p. 49 • Is there a role for selective progesterone receptor modulators in management of uterine bleeding? - K. Chwalisz (USA) p. 61 • Should menstruation be optional? – Health benefits of amenorrhoea – D. Baird (UK) p. 72 PRE-CONGRESS COURSE 4 - PROGRAMME SIG Endometriosis & Endometrium Abnormal uterine bleeding: strategies for management Course co-ordinators: H. Critchley (UK) & Th. D’Hooghe (B) Course description: Problematic uterine bleeding impairs quality of life for many women and often involves invasive treatments and significant cost. Agreement is needed on terminology and defi nitions in order to facilitate the establishment of multi-centre clinical trials evaluating the strategies for management. Contemporary management also requires an understanding of the patient’s perspective of her complaint and an understanding of acceptability to women of the available modes of investigation and treatment options. Optimal therapies will only be possible with a detailed understanding of the mechanisms involved in endometrial bleeding including unscheduled bleeding with exogenous hormone administration. Novel therapies need to be evaluated in the context of potential health benefits from therapies that reduce the number of menstrual cycles experienced by women.
    [Show full text]
  • OECD Environment Health and Safety Publications Series on Testing and Assessment No
    OECD Environment Health and Safety Publications Series on Testing and Assessment No. 21 Detailed Review Paper Appraisal of Test Methods for Sex Hormone Disrupting Chemicals Environment Directorate ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT Paris May 2001 1 Also Published in the Series Testing and Assessment: No. 1, Guidance Document for the Development of OECD Guidelines for Testing of Chemicals (1993; reformatted 1995) No. 2, Detailed Review Paper on Biodegradability Testing (1995) No. 3, Guidance Document for Aquatic Effects Assessment (1995) No. 4, Report of the OECD Workshop on Environmental Hazard/Risk Assessment (1995) No. 5, Report of the SETAC/OECD Workshop on Avian Toxicity Testing (1996) No. 6, Report of the Final Ring-test of the Daphnia magna Reproduction Test (1997) No. 7, Guidance Document on Direct Phototransformation of Chemicals in Water (1997) No. 8, Report of the OECD Workshop on Sharing Information about New Industrial Chemicals Assessment (1997) No. 9 Guidance Document for the Conduct of Studies of Occupational Exposure to Pesticides During Agricultural Application (1997) No. 10, Report of the OECD Workshop on Statistical Analysis of Aquatic Toxicity Data (1998) No. 11, Detailed Review Paper on Aquatic Testing Methods for Pesticides and industrial Chemicals (1998) No. 12, Detailed Review Document on Classification Systems for Germ Cell Mutagenicity in OECD Member Countries (1998) No. 13, Detailed Review Document on Classification Systems for Sensitising Substances in OECD Member Countries 1998) No. 14, Detailed Review Document on Classification Systems for Eye Irritation/Corrosion in OECD Member Countries (1998) No. 15, Detailed Review Document on Classification Systems for Reproductive Toxicity in OECD Member Countries (1998) No.
    [Show full text]
  • 2019 AAPLOG Position Statement on Abortion Pill Reversal
    2019 AAPLOG Position Statement on Abortion Pill Reversal Some women change their mind about abortion after taking the first drug of the abortion regimen. For those women, Abortion Pill Rescue offers a medically sound choice to attempt to reverse the effects of Mifepristone, and to save their baby. The American Association of Pro-Life Obstetricians and Gynecologists strongly supports efforts to require all women presenting for abortion to be given information about abortion pill reversal as part of informed consent prior to abortion. Biological Background on the Chemical Abortion Regimen and Abortion Pill Reversal The chemical abortion regimen consists of two drugs: Mifeprex (a.k.a. mifepristone or RU-486) and Cytotec (misoprostol). Mifeprex is the first drug developed in a class of drugs called “selective progesterone receptor blockers”. This class also includes Ella (ulipristal) and onapristone among others. Mifeprex is the first drug approved by the FDA for inducing abortion. However, Mifeprex by itself is only effective at accomplishing embryo demise about 75% of the time1. So, roughly one out of four women who take Mifeprex alone will have an unborn child in utero who continues to live. So, in order to increase the number of women who complete the abortion, a second drug, Cytotec (misoprostol), is administered to the woman. Cytotec is of the class of drugs known as prostaglandins. Other prostaglandins can also be used for this purpose (e.g. gemeprost) Prostaglandins cause the uterus to contract, forcing the expulsion of the unborn
    [Show full text]
  • Effects of a Novel Estrogen-Free, Progesterone Receptor Modulator
    Edinburgh Research Explorer Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women Citation for published version: Brache, V, Sitruk-Ware, R, Williams, A, Blithe, D, Croxatto, H, Kumar, N, Kumar, S, Tsong, Y-Y, Sivin, I, Nath, A, Sussman, H, Cochon, L, Miranda, MJ, Reyes, V, Faundes, A & Mishell, D 2012, 'Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women', Contraception, vol. 85, no. 5, pp. 480-8. https://doi.org/10.1016/j.contraception.2011.10.003 Digital Object Identifier (DOI): 10.1016/j.contraception.2011.10.003 Link: Link to publication record in Edinburgh Research Explorer Document Version: Peer reviewed version Published In: Contraception Publisher Rights Statement: NIH Public access author manuscript General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 26. Sep. 2021 NIH Public Access Author Manuscript Contraception. Author manuscript; available in PMC 2013 May 01.
    [Show full text]
  • Schwerpunkt 40 Jahre Pille
    Familienplanungs- RUNDBRIEF Ausgabe Juni 2000 Nr. 1/2 Inhalt Einleitung 3 Hormonelle Kontrazeption: 40 Jahre Pille 4 – Entwicklungen, die zur Herstellung der Pille führten 4 – Weiterentwicklung der Pille von 1960 bis heute 8 – Die gesellschaftspolitische Bedeutung der Pille 12 – Hormonelle Kontrazeptiva heute in Deutschland 14 – Anwendung der hormonalen Kontrazeptiva nach dem heutigen 17 Wissensstand – Wechselwirkungen 24 Anhang (Ende des Dokuments) – Medikamente, die die Sicherheit A1 der Pille beeinträchtigen können – Liste hormonaler Kontrazeptiva A2 IPPF Informationen – Gestagen-Implantate 27 Forum – Vorgeburtliche Untersuchungen: 28 Möglichkeiten und Grenzen Veranstaltungskalender 29 Stichwortverzeichnis 1999 31 Deutsche Gesellschaft für Familienplanung, Sexualpädagogik und Sexualberatung e.V., Bundesverband e.V., Sexualberatung und Sexualpädagogik für Familienplanung, Gesellschaft Deutsche Stresemannallee 3, 60596 Frankfurt am Main, Telefon 069/639002 Impressum: 2000 Herausgeber: PRO FAMILIA-Bundesverband Redaktion: Dr. med. Ruth Eichmann, Frankfurt am Main Dr. med. Ines Thonke, Frankfurt am Main Dr. med. Jutta Walter, Heidelberg Anschrift: PRO FAMILIA-Bundesverband Stresemannallee 3 60596 Frankfurt am Main Gefördert von der Bundeszentrale für gesundheitliche Aufklärung (BZgA). Familienplanungs- RUNDBRIEF Juni 2000 Nr. 1/2 3 In der Rubrik „HINWEISE“ wird wie üblich in dem Einleitung jeweiligen Familienplanungs-Rundbrief Aktuelles aus der Medizin zu finden sein, das von besonde- rer Bedeutung für die Beratungspraxis ist. Lite- raturneuerscheinungen und Ankündigungen von Veranstaltungen runden die einzelnen Familien- planungs-Rundbriefe ab. In Übereinstimmung mit der gewohnten Gliede- rung befasst sich der erste Familienplanungs- Beibehalten wird ferner der Abschnitt, in welchem Rundbrief des Jahres mit einer Vorschau auf die aktuelle Informationen der IPPF (International im laufenden Jahr geplanten Schwerpunktthe- Planned Parenthood Federation) aufgenommen men. Dafür vorgesehen sind: werden, soweit sie medizinischen Inhalts sind.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Asoprisnil: a Selective Progesterone Receptor Modulator
    Molecules of the Millennium Asoprisnil: A selective progesterone receptor modulator Progesterone is a hormone that is secreted by the corpus agonist–antagonist at progesterone receptors. Asoprisnil has luteum, placenta, and in minimal quantities by the testis and an antagonistic effect on the endometrium, ovary, and breast adrenal cortex. The important function of progesterone is to tissue. It has no effect or partial agonistic effect on myometrium sustain pregnancy. Large doses of progesterone inhibit LH of pregnant uterus, whereas in myometrium of leiomyoma it surge and potentiate the inhibitory effect of estrogen on acts as an antagonist. hypothalamus–pituitary axis, preventing ovulation. Therefore, On endometrium synthetic substances which are agonist at progesterone The selective progesterone receptor modulators cause receptor called “progestins” were developed, and these atrophy of the endometrium. Both selective progesterone substances became an essential constituent of oral receptor modulators and progesterone antagonists make the contraceptive pills. Progestins are mitogenic for breast blood vessels that supply blood to the endometrium robust, epithelium and increase mammographic shadow. Clinical trials whereas they become fragile with progestins. Both have shown that progestins and estrogens, and not estrogen progesterone antagonists and SPRMs cause amenorrhea. But alone, cause an increased incidence of breast cancer in the way in which both these group of drugs cause amenorrhea postmenopausal women.[1,2] Progesterone receptor
    [Show full text]
  • A Novel Male Contraceptive Pill-Patch Combination: Oral Desogestrel and Transdermal Testosterone in the Suppression of Spermatogenesis in Normal Men
    0013-7227/01/$03.00/0 The Journal of Clinical Endocrinology & Metabolism 86(11):5201–5209 Printed in U.S.A. Copyright © 2001 by The Endocrine Society A Novel Male Contraceptive Pill-Patch Combination: Oral Desogestrel and Transdermal Testosterone in the Suppression of Spermatogenesis in Normal Men W. MORTON HAIR, KAY KITTERIDGE, DARYL B. O’CONNOR, AND FREDERICK C. W. WU Department of Endocrinology, Manchester Royal Infirmary, University of Manchester, Manchester, United Kingdom Downloaded from https://academic.oup.com/jcem/article/86/11/5201/2849291 by guest on 29 September 2021 M13 9WL This study investigated the effect of transdermal T and oral a dose of 75 ␮g was ineffective (0% azoospermic). Total and desogestrel on the reproductive axis of healthy men. Twenty- free plasma T were reduced by approximately 30%. High den- three men were randomized to 1 of 3 treatment groups and sity lipoprotein cholesterol was significantly reduced. No se- received a daily transdermal T patch plus oral desogestrel at rious side-effects were encountered. We conclude that daily a dose of 75, 150, or 300 ␮g/d for 24 wk. Baseline blood and self-administered desogestrel with transdermal T is capable semen samples were obtained and then every 4 wk thereafter of suppressing the male reproductive axis, although the effi- for 32 wk. The outcome measures were sperm density and cacy was less marked and less consistent than injectable reg- plasma levels of FSH, LH, total and free T. The results show a imens. The lower efficacy is likely to be due to failure of the dose-dependent suppression of spermatogenesis and gonad- transdermal T system to maintain circulating T levels consis- otropins.
    [Show full text]
  • Failure of Male Contraception: an Insight Siuli Mitra* and Gautam Kumar Kshatriya Department of Anthropology, University of Delhi, Delhi, India
    hropolo nt gy A Mitra and Kshatriya, Anthropol 2014, 2:2 Anthropology DOI: 10.4172/2332-0915.1000119 ISSN: 2332-0915 CommentaryResearch Article OpenOpen Access Access Failure of Male Contraception: An Insight Siuli Mitra* and Gautam Kumar Kshatriya Department of Anthropology, University of Delhi, Delhi, India Introduction Before the revolution brought about by OCPs contraceptive options were limited to withdrawal, periodic abstinence and/or condoms [5]. Contraception is the answer to the surmounting pressure Subsequent development of Intra-uterine devices (IUDs) and tubal on ecology and economy caused by rapid population growth. surgical sterilization shifted the focus on women. After the latter gained Contraception is decreasing fertility in humans to prevent conception popularity the males gradually felt unimportant participating in a of an offspring. Conceiving and bearing a child is among the most service that is female-targeted. Eventually females became the clientele significant aspects of human existence. But limitations of a human body of family planning programmes and contraceptive methods available to conceive too many offspring and socio-economic factors constrain for women outnumbered those for males. Assumptions like men want having too many children in human societies. That is how the idea of more children, do not want to share responsibility of child rearing contraception was realized and different modes of contraception were and averse to contraception, have made them less preferred targets of devised to be directed at both males and females. However female family planning programmes. But recent surveys have denounced this contraception continues to be the more popular choice among couples attitude in men and shown that men are showing increased interest in in all human societies.
    [Show full text]
  • The Clinical Efficacy of Progesterone Antagonists in Breast Cancer ------ .__..__
    8 The clinical efficacy of progesterone antagonists in breast cancer --------_.__..__. Walter Jonat, Marius Giurescu, John FR Robertson CONTENTS • Introduction • Onapristone • Mlfepristone • Summary INTRODUCTION indication of a functional PgR.4 As described in Chapter 14, substantial in vitro and in vivo The search for active and safe alternatives to evidence suggests that PgR serves as a biologi­ current systemic therapies is one of the main cally important molecule in breast cancer objectives of current breast cancer research. behaviour. Moreover, preclinical studies indi­ Over the last three decades since the discovery cate that blockade of PgR function inhibits pro­ of the estrogen receptor (ER), the development liferation and induces apoptosis (see Chapter of new endocrine agents has in the main been 14). Therefore, clinically practical PgR inhibitors aimed at either preventing the production of have been developed. These are overtly active estrogens (e.g. ovarian ablation with small molecuk'S that appear to function by gonadotropin-releasing hormone (GnRH) ana­ binding to PgR and inhibiting pathways down­ logues, aromatase inhibition) or blocking their stream of PgR. Two agents, onapristone and effect by competition for ER (e.g. selective ER mifepristone, have been evaluated in clinical modulators (SERMs) and pure antiestrogens). trials, and, as described below, have activity in Such developments have focused, indirectly or patients with metastatic disease. Although com­ directly, on the ER as a target for manipulation mercial support for these two agents has of tumour growth. This approach is supported recently waned, the concept of PgR inhibition by the finding that the response to such thera­ in breast cancer is sufficiently well founded to pies is related to the expression of ER by breast justify its inclusion in any textbook of endocrine tumours.13 However, it is also known that therapy.
    [Show full text]
  • EC313-A Tissue Selective SPRM Reduces the Growth and Proliferation of Uterine Fbroids in a Human Uterine Fbroid Tissue Xenograft Model Hareesh B
    www.nature.com/scientificreports OPEN EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fbroids in a human uterine fbroid tissue xenograft model Hareesh B. Nair1*, Bindu Santhamma1, Kalarickal V. Dileep2, Peter Binkley3, Kirk Acosta1, Kam Y. J. Zhang 2, Robert Schenken3 & Klaus Nickisch1 Uterine fbroids (UFs) are associated with irregular or excessive uterine bleeding, pelvic pain or pressure, or infertility. Ovarian steroid hormones support the growth and maintenance of UFs. Ulipristal acetate (UPA) a selective progesterone receptor (PR) modulator (SPRM) reduce the size of UFs, inhibit ovulation and lead to amenorrhea. Recent liver toxicity concerns with UPA, diminished enthusiasm for its use and reinstate the critical need for a safe, efcacious SPRM to treat UFs. In the current study, we evaluated the efcacy of new SPRM, EC313, for the treatment for UFs using a NOD-SCID mouse model. EC313 treatment resulted in a dose-dependent reduction in the fbroid xenograft weight (p < 0.01). Estradiol (E2) induced proliferation was blocked signifcantly in EC313-treated xenograft fbroids (p < 0.0001). Uterine weight was reduced by EC313 treatment compared to UPA treatment. ER and PR were reduced in EC313-treated groups compared to controls (p < 0.001) and UPA treatments (p < 0.01). UF specifc desmin and collagen were markedly reduced with EC313 treatment. The partial PR agonism and no signs of unopposed estrogenicity makes EC313 a candidate for the long-term treatment for UFs. Docking studies have provided a structure based explanation for the SPRM activity of EC313. Te unmet need for medical management of uterine fbroids (UFs) has led to the discovery of various novel agents in recent years.
    [Show full text]